文献速递类风湿关节炎

乌帕替尼或阿达木单抗联合甲氨蝶呤治疗类风湿关节炎48周安全性及换药疗效

Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.
PubMed 文献 · Ann Rheum Dis · 2019-07-30

SELECT-COMPARE随机双盲研究报道,乌帕替尼15 mg每日一次联合甲氨蝶呤治疗类风湿关节炎,26至48周在低疾病活动度、临床缓解及疼痛功能改善方面持续优于阿达木单抗,影像学进展抑制优于安慰剂。对原药应答不足者不经洗脱换用另一种药物仍可获得临床有意义应答,48周安全性与26周相当。

要点

  • 乌帕替尼联合甲氨蝶呤48周临床与功能应答持续优于阿达木单抗联合甲氨蝶呤
  • 乌帕替尼对结构损伤进展的抑制在48周时仍优于安慰剂
  • 阿达木单抗或乌帕替尼应答不足者不经洗脱换药可安全获得有意义应答

核心结论

  • 乌帕替尼联合甲氨蝶呤在48周内临床和功能应答优于阿达木单抗联合甲氨蝶呤,并维持对结构损伤的抑制。
  • 对阿达木单抗或乌帕替尼应答不足者换用另一种药物后仍可获得临床有意义应答,且安全性可接受。

研究设计与样本

  • SELECT-COMPARE为随机双盲研究,患者在接受甲氨蝶呤背景治疗下接受乌帕替尼15 mg、安慰剂或阿达木单抗治疗48周。
  • 若患者压痛关节数或肿胀关节数改善<20%(第14/18/22周)或CDAI>10(第26周),则不经洗脱从安慰剂或阿达木单抗换用乌帕替尼,或从乌帕替尼换用阿达木单抗;剩余安慰剂组患者在26周换用乌帕替尼。
  • 疗效按随机分组分析(非应答者填补),并对换药患者另行分析(实际观察值);治疗中出现的不良事件按每100患者年汇总。

主要发现

  • 26至48周,乌帕替尼组按随机分组分析的应答(包括低疾病活动度、临床缓解及疼痛和功能改善)持续优于阿达木单抗组。
  • 影像学进展方面,乌帕替尼组仍低于安慰剂组(线性外推)。
  • 两个换药组均有应答,但从阿达木单抗换用乌帕替尼的患者在换药后6个月达到CDAI≤10的比例高于从乌帕替尼换用阿达木单抗的患者。
  • 第48周安全性与第26周相当。

关键数值与推荐

  • 换药触发条件:压痛关节数或肿胀关节数改善<20%(第14/18/22周评估),或CDAI>10(第26周)。
  • 主要疗效观察指标包括低疾病活动度、临床缓解、疼痛与功能改善及影像学进展。

临床怎么用

  • 对甲氨蝶呤背景治疗下应答不足的类风湿关节炎患者,可考虑乌帕替尼与阿达木单抗之间不经洗脱直接换药。
  • 换药后需继续评估CDAI等疾病活动度指标及安全性,关注48周内的持续应答。

局限性

  • 摘要未报告具体样本量、效应值、置信区间及不良事件发生率。
  • 换药患者的分析为实际观察值,非随机比较,解读需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In SELECT-COMPARE, a randomised double-blind study, upadacitinib 15 mg once daily was superior to placebo or adalimumab on background methotrexate (MTX) for treating rheumatoid arthritis signs and symptoms and inhibited radiographical progression versus placebo at 26 weeks. Here we report 48-week safety and efficacy in patients who continued their original medication or were rescued to the alternative medication for insufficient response. METHODS: Patients on MTX received upadacitinib 15 mg, placebo or adalimumab for 48 weeks. Rescue without washout, from placebo or adalimumab to upadacitinib or upadacitinib to adalimumab occurred if patients had <20% improvement in tender joint count (TJC) or swollen joint count (SJC) (weeks 14/18/22) or Clinical Disease Activity Index (CDAI) >10 (week 26); remaining placebo patients were switched to upadacitinib at week 26. Efficacy was analysed by randomised group (non-responder imputation), as well as separately for rescued patients (as observed). Treatment-emergent adverse events per 100 patient-years were summarised. RESULTS: Consistent with responses through week 26, from weeks 26 to 48, responses by randomised group including low disease activity, clinical remission and improvements in pain and function remained superior for upadacitinib versus adalimumab; radiographical progression remained lower for upadacitinib versus placebo (linear extrapolation). Although both switch groups responded, a higher proportion of patients rescued to upadacitinib from adalimumab achieved CDAI ≤10 at 6 months postswitch versus patients rescued from upadacitinib to adalimumab. Safety at week 48 was comparable to week 26. CONCLUSION: Upadacitinib+MTX demonstrated superior clinical and functional responses versus adalimumab+MTX and maintained inhibition of structural damage versus placebo+MTX through week 48. Patients with an insufficient response to adalimumab or upadacitinib safely achieved clinically meaningful responses after switching to the alternative medication without washout.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Fleischmann RM, Genovese MC, Enejosa JV, et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis. 2019. PMID: 31362993. doi:10.1136/annrheumdis-2019-215764

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。